RALEIGH, N.C.--(BUSINESS WIRE)--Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), an innovative medicines company..

北卡罗来纳州罗利市（商业新闻短讯）--林迪生物科学公司是一家专注于创新药物配方和递送技术的开创性生物技术公司，今天宣布与创新药物公司诺华公司（NYSE:NVS）的子公司诺华制药公司（Novartis Pharma AG）达成多目标独家全球许可协议和战略合作。。

The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Biosciences’ proprietary microglassification suspension technology. By delivering high concentrations of biologics, this technology significantly increases the maximum dose that can be administered in a single subcutaneous injection.

此次合作的重点将是使用林迪生物科学专有的微玻璃化悬浮技术，将诺华投资组合中的部分创新药物转变为方便、自我管理的皮下注射。通过提供高浓度的生物制剂，该技术显着增加了单次皮下注射可施用的最大剂量。

This has the potential to reduce healthcare costs while also improving patient comfort, convenience, and treatment compliance..

这有可能降低医疗保健成本，同时提高患者的舒适度，便利性和治疗依从性。。

Currently, over half of all antibody therapeutics are administered intravenously in a clinical setting, primarily due to the high doses required that cannot be formulated in volumes suitable for subcutaneous injection. Lindy Biosciences’ proprietary microglassification platform technology is poised to transform this paradigm by enabling self-administration at home via pre-filled syringes or autoinjectors..

目前，超过一半的抗体治疗剂是在临床环境中静脉内给药的，主要是由于所需的高剂量不能配制成适合皮下注射的体积。Lindy Biosciences专有的微玻璃化平台技术有望通过预先填充的注射器或自动注射器在家中实现自我管理，从而改变这种模式。。

Strategic Impact and Future Outlook

战略影响和未来展望

Dr. Deborah Bitterfield, founder and CEO of Lindy Biosciences, expressed enthusiasm about the collaboration: 'We're excited to deepen our collaboration with Novartis. This collaboration is a testament to our shared dedication to enhancing patient care and marks a significant milestone as we take Lindy’s formulation technology into the clinic for the first time.

林迪生物科学公司（Lindy Biosciences）创始人兼首席执行官黛博拉·比特菲尔德（Deborah Bitterfield）博士对此次合作表示了热情：“我们很高兴能深化与诺华的合作。这次合作证明了我们共同致力于加强患者护理，这是我们首次将Lindy的配方技术引入临床的一个重要里程碑。

Together, we aim to transform drug delivery and improve treatment access for patients worldwide.'.

我们共同致力于改变药物输送方式，改善全球患者的治疗机会。”。

The agreement's financial terms include an upfront payment of US$20 million to Lindy Biosciences. Lindy Biosciences is also eligible to receive up to US$934 million in additional payments across multiple targets upon achieving certain regulatory, development and commercial milestones as well as tiered single-digit royalties on net sales..

该协议的财务条款包括向Lindy Biosciences支付2000万美元的预付款。林迪生物科学（Lindy Biosciences）还可以在实现某些监管、开发和商业里程碑以及净销售额分层的单位数字版税后，在多个目标上获得高达9.34亿美元的额外付款。。

This collaboration marks a significant step forward in addressing the growing need for patient-friendly treatment options that can be self-administered at home. By combining innovative technology from Lindy Biosciences and the global reach and expertise of Novartis, the collaboration promises to usher in a new era of drug delivery, reshaping patient care on a global scale..

这一合作标志着在满足日益增长的对患者友好的治疗选择的需求方面迈出了重要的一步，这些治疗选择可以在家中自我管理。通过将林迪生物科学的创新技术与诺华的全球影响力和专业知识相结合，该合作有望开创药物输送的新时代，在全球范围内重塑患者护理。。

About Lindy Biosciences

关于林迪生物科学

Lindy Biosciences is dedicated to transforming the delivery of biologic drugs and improving patients' lives through innovative biotherapeutic formulations. Our cutting-edge solutions are designed to enhance drug formulation and delivery, specializing in the subcutaneous administration of concentrated (>400 mg/mL) biologic suspensions..

Lindy Biosciences致力于通过创新的生物治疗配方来改变生物药物的输送并改善患者的生活。。。

Founded in 2016 and headquartered in Morrisville, NC, Lindy Biosciences leverages core microglassification technology originated at Duke University and further developed by the company. We are committed to partnering with leading pharmaceutical companies to advance treatment accessibility for patients worldwide..

林迪生物科学公司成立于2016年，总部位于北卡罗来纳州莫里斯维尔，利用杜克大学（Duke University）研发的核心微玻璃化技术。我们致力于与领先的制药公司合作，以提高全球患者的治疗可及性。。

For more information, visit us at www.lindybio.com or follow us on LinkedIn.

有关更多信息，请访问www.lindybio.com或在LinkedIn上关注我们。